{"id":"W3004888955","doi":"10.1200/jco.2020.38.4_suppl.1","title":"Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pembrolizumab; Clinical endpoint; Internal medicine; Phases of clinical research; Surgery; Cancer; Oncology; Gastroenterology; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.001829232,0.0002470262,0.001797409,0.00005584333,0.0001611378,0.00001449654,0.0004020234,0.0002882757,0.0000974229],"category_scores_gemma":[0.01010782,0.0001468157,0.001023553,0.0002013699,0.0001890105,0.0001011292,0.0001661475,0.001370783,0.00001538123],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001058051,"about_ca_system_score_gemma":0.001218598,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008035689,"about_ca_topic_score_gemma":0.0001294804,"domain_scores_codex":[0.9951938,0.000468173,0.003050661,0.0004262867,0.0005036393,0.0003574762],"domain_scores_gemma":[0.9900648,0.006520063,0.001777171,0.0002952874,0.0005907194,0.0007519736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5491427,0.02871139,0.1156554,0.00008672542,0.0007415565,0.005814935,0.006566884,0.0001589496,0.006220043,0.00002557146,0.04825274,0.2386231],"study_design_scores_gemma":[0.2083966,0.2997986,0.3787239,0.00003539567,0.002164131,0.0001534817,0.002902538,0.003835123,0.0007245106,0.0001355242,0.1028219,0.0003082532],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.968964,0.0005541769,0.0001084254,0.02718726,0.0009898301,0.0008493492,0.00009675939,0.00001706584,0.001233093],"genre_scores_gemma":[0.9879886,0.00003214295,0.001102539,0.006067376,0.004460823,0.000009264668,0.00002049454,0.00002859689,0.0002901905],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.340746,"threshold_uncertainty_score":0.9982305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1401134497973141,"score_gpt":0.4451741765726717,"score_spread":0.3050607267753576,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}